This antibody can be potentially used in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (RA). It can strongly cross-reacts with human PAD2.
Figure 1 Inhibitory capacity of anti-PAD2 mAbs. The ability of selected anti-PAD2 mAbs to inhibit citrullination of fibrinogen was tested using human recombinant PAD2 (hrPAD2) as catalyst.
Test of the inhibitory capacity of mAbs #6, #8 and #10. Anti-C4 was used as control.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-1858-VHH | Recombinant Anti-Human PADI2 VHH Single Domain Antibody | ICC, FC, WB, FUNC | Llama VHH |
There are currently no Customer reviews or questions for TAB-0921CL-F(E). Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.